An investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence (SUI), reports a placebo-controlled clinical trial in the August issue of The Journal of Urology. “Our study adds new evidence that TAS-303 reduces the frequency of incontinence episodes in women with SUI, without the worrisome adverse effects associated with the existing SUI medication duloxetine,” comments Prof. Momokazu Gotoh of Chukyo Hospital, Nagoya, Japan. A safer medication option for treatment of SUI? Stress urinary incontinence—defined as leakage on exertion or with sneezing or coughing—is Read More